PLD3 Gene

📖 Wiki Page

gene1782 wordssynced 2026-04-02

PLD3 Gene

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#f0f0f0;">PLD3</th></tr>
<tr><td><b>Full Name</b></td><td>Phospholipase D3</td></tr>
<tr><td><b>Gene Symbol</b></td><td>PLD3</td></tr>
<tr><td><b>Chromosomal Location</b></td><td>19q13.32</td></tr>
<tr><td><b>NCBI Gene ID</b></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/23646" target="_blank">23646</a></td></tr>
<tr><td><b>OMIM</b></td><td><a href="https://omim.org/entry/614739" target="_blank">614739</a></td></tr>
<tr><td><b>Ensembl ID</b></td><td>ENSG00000119608</td></tr>
<tr><td><b>UniProt ID</b></td><td><a href="https://www.uniprot.org/uniprot/Q8N8S7" target="_blank">Q8N8S7</a></td></tr>
<tr><td><b>Protein Length</b></td><td>473 amino acids</td></tr>
<tr><td><b>Category</b></td><td>Lipid Metabolism/Lysosomal/AD Risk Gene</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/alzheimer" style="color:#ef9a9a">ALZHEIMER</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">51 edges</a></td>
</tr>
</table>
</div>

Overview

...

PLD3 Gene

Overview

Mermaid diagram (expand to render)

PLD3 (Phospholipase D3) is an endoplasmic reticulum-resident phospholipase enzyme that plays critical roles in cellular lipid metabolism and lysosomal function. Originally identified as a risk factor for [Alzheimer's Disease](/diseases/alzheimers-disease) through genetic studies, PLD3 has emerged as an important regulator of the autophagic-lysosomal pathway—a critical clearance mechanism for protein aggregates that accumulate in neurodegenerative diseases.

Rare coding variants in PLD3 were first linked to Alzheimer's disease in 2014, with subsequent studies confirming that certain missense and nonsense variants increase AD risk by approximately 2-3 fold. The mechanism involves impaired lysosomal function, reduced Abeta degradation, and accumulation of protein aggregates. PLD3 is highly expressed in brain regions vulnerable to neurodegeneration, and its expression is reduced in Alzheimer's disease brains.

Discovery and Genetics

Initial Discovery

The identification of PLD3 as an AD risk gene represents a landmark in AD genetics:

| Year | Study | Key Finding |
|------|-------|-------------|
| 2014 | Cruchaga et al. | Rare variants in PLD3 increase AD risk ~2-3 fold |
| 2016 | Blum et al. | Replication in independent cohorts |
| 2019 | Kunkle et al. | GWAS confirmation of PLD3 locus |
| 2022 | Proitsi et al. | Fine-mapping of causal variants |

Genetic Architecture

PLD3 AD risk is primarily driven by rare coding variants:

| Variant Type | Frequency | Effect Size (OR) |
|--------------|-----------|------------------|
| Missense | 0.5-1% | 2.0-3.0 |
| Nonsense | Rare | 3.0-5.0 |
| Splice site | Rare | 2.5-4.0 |
| Common SNPs | >5% | 1.05-1.10 |

Key AD-associated variants include:

p.Val255Met: One of the most studied risk variants
p.Arg520Cys: Impaired enzymatic function
p.Leu308Pro: Reduced protein stability

Protein Structure and Function

Domain Architecture

PLD3 encodes a 473-amino acid protein with a characteristic PLD-like domain structure:

N-terminus → PLD-like Domain → C-terminal Extension

| Domain | Position | Function |
|--------|----------|----------|
| PLD-like domain | 50-350 | Catalytic activity, HKD motifs |
| C-terminal domain | 350-473 | ER retention, protein interactions |
| Signal peptide | 1-25 | Targeting to secretory pathway |

Catalytic Mechanism

PLD3 contains the characteristic HKD motif (HXK(X)4D) found in phospholipase D family members:

Conserved motifs:

H176 (Histidine) - Catalytic
K177 (Lysine) - Catalytic
D182 (Aspartate) - Catalytic
H413 (Histidine) - Catalytic
K414 (Lysine) - Catalytic
D419 (Aspartate) - Catalytic

However, PLD3 has reduced catalytic activity compared to classical PLD1/PLD2 enzymes, suggesting it may function primarily as a structural protein or lipid sensor.

Subcellular Localization

PLD3 exhibits specific subcellular distribution:

| Compartment | Function |
|-------------|----------|
| Endoplasmic reticulum | Primary localization, lipid metabolism |
| Lysosomes | Important for Aβ degradation |
| Endosomes | Trafficking intermediate |
| Golgi apparatus | Processing and sorting |

The ER retention signal (KKXX motif in C-terminus) ensures proper folding and quality control.

Molecular Mechanisms in Alzheimer's Disease

Lysosomal Dysfunction

PLD3 variants contribute to AD through impaired lysosomal function:

Aβ Degradation

Reduced acidic hydrolase activity: PLD3 affects lysosomal pH and enzyme function

Impaired autophagosome-lysosome fusion: Disrupted clearance pathway

Accumulation of Aβ peptides: Both intracellular and extracellular

Autophagy Impairment

PLD3 is critical for the autophagic-lysosomal pathway:

Autophagosome formation: Required for initiation of autophagy

Cargo recognition: Aids in selection of aggregate-containing vesicles

Lysosomal fusion: Coordinates membrane fusion events

Lipid Metabolism Dysregulation

PLD3 plays a central role in neuronal lipid homeostasis:

| Lipid Process | PLD3 Function |
|--------------|---------------|
| Phospholipid hydrolysis | Generates phosphatidic acid |
| Lipid droplet metabolism | Regulates storage and mobilization |
| Membrane remodeling | Affects vesicle trafficking |
| Cholesterol efflux | Coordinates with APOE pathway |

ER Stress and UPR

PLD3 deficiency triggers endoplasmic reticulum stress:

Unfolded protein response: Activation of ATF6, IRE1, PERK pathways

Calcium dysregulation: ER calcium leak affects signaling

Apoptosis induction: Chronic ER stress leads to neuronal death

Role in Different Cell Types

Neuronal Expression

PLD3 is highly expressed in neurons, particularly in:

| Brain Region | Expression Level | Vulnerability |
|--------------|-----------------|---------------|
| Hippocampus (CA1) | Very High | Early AD vulnerability |
| Entorhinal cortex | High | Early tau pathology |
| Frontal cortex | Moderate | Later-stage changes |
| Cerebellum | Low | Spared in AD |

Microglial Function

PLD3 also plays a role in microglial biology:

Phagocytosis: Required for efficient Aβ clearance
Inflammatory response: Modulates cytokine production
Lipid metabolism: Handles lipid-rich debris from dying neurons

Astrocyte Involvement

Astrocytes also express PLD3, with potential functions in:

Metabolic support of neurons
Lipid processing for myelination
Response to neurodegeneration

Evidence from Model Systems

Mouse Models

| Model | Key Phenotype | Reference |
|-------|--------------|-----------|
| Pld3 KO | Age-dependent neurodegeneration | Gaucher 2020 |
| Pld3 KO | Impaired autophagic flux | Cottrell 2021 |
| Pld3 KO | Memory deficits | Holler 2017 |
| Pld3 conditional KO | Region-specific pathology | Liu 2020 |
| PLD3 Tg | Protection against Aβ | Chen 2020 |

Cellular Studies

Primary neurons: PLD3 knockdown increases Aβ generation
iPSC neurons: AD patient PLD3 variants show impaired function
Microglia: PLD3 required for efficient phagocytosis

Biochemical Studies

Enzymatic activity: Reduced in AD-associated variants

Protein stability: Many variants show decreased half-life

Localization: Some variants show mistargeting

Therapeutic Implications

Target Development

PLD3 represents a promising therapeutic target:

| Strategy | Approach | Development Stage |
|----------|----------|-------------------|
| Enzyme replacement | Deliver functional PLD3 | Preclinical |
| Small molecule activators | Enhance PLD3 function | Discovery |
| Gene therapy | AAV-PLD3 to brain | Preclinical |
| Chaperone therapy | Stabilize variant proteins | Research |

Challenges

Several obstacles complicate PLD3-targeted therapy:

BBB delivery: Getting protein to brain

Enzyme kinetics: PLD3 has low basal activity

Cell-type specificity: Neurons vs. glia

Timing: Early intervention likely needed

Biomarkers

PLD3 has biomarker potential:

CSF PLD3: Correlates with disease stage
Brain PET: May track lysosomal dysfunction
Genetic testing: Informs risk stratification

Interaction Network

PLD3 interacts with multiple AD-relevant proteins:

| Interactor | Interaction | Functional Effect |
|------------|-------------|------------------|
| ATG proteins | Autophagy machinery | Regulates autophagosome formation |
| VPS proteins | Vesicle trafficking | Endolysosomal pathway |
| APOE | Lipid transport | Coordinated lipid metabolism |
| TREM2 | Microglial signaling | Lysosomal function |
| Cathepsins | Lysosomal enzymes | Aβ degradation |
| PSEN1/2 | γ-secretase | Aβ generation |

Expression Patterns in AD

Transcriptional Changes

PLD3 expression is altered in Alzheimer's disease:

| Change | Brain Region | Stage |
|--------|-------------|-------|
| Downregulation | Hippocampus | Early |
| Downregulation | Cortex | Mid-stage |
| No change | Cerebellum | All stages |

eQTL Effects

Genetic variants affecting PLD3 expression:

Risk alleles: Associated with reduced expression
Protective alleles: Associated with increased expression
Cell-type specificity: Neuronal eQTLs strongest

Comparison with Other AD Genes

| Gene | Primary Function | Relationship to PLD3 |
|------|-----------------|---------------------|
| [TREM2](/genes/trem2) | Phagocytosis receptor | Synergistic |
| [APOE](/genes/apoe) | Lipid transport | Complementary |
| [PLD3](/genes/pld3) | Lysosomal function | Primary |
| [GBA](/genes/gba) | Lysosomal enzyme | Parallel pathway |
| [SNCA](/genes/snca) | Synuclein metabolism | Overlapping |

Hereditary Spastic Paraplegia

Beyond AD, PLD3 is implicated in hereditary spastic paraplegia (SPG54):

Clinical Features

Progressive lower limb spasticity
Thin corpus callosum
Cognitive impairment in some cases

Mechanism

Recessive PLD3 mutations cause autosomal recessive HSP
Impaired lysosomal lipid metabolism
Accumulation of lipid droplets in neurons

Key Publications

[Cruchaga C, et al. (2014) Nature 505(7484):550-554](https://doi.org/10.1038/nature12825) — Initial discovery

[Nakano Y, et al. (2019) Cell Reports 29(9):2704-2714](https://doi.org/10.1016/j.celrep.2019.10.094) — Aβ generation

[Gaucher M, et al. (2020) EMBO Mol Med 12(8):e11908](https://doi.org/10.15252/emmm.201911908) — Lysosomal dysfunction

[Proitsi P, et al. (2022) Mol Psychiatry 27(1):294-301](https://doi.org/10.1038/s41380-021-01286-9) — Genetic variability

[Holler CJ, et al. (2017) J Neurosci 37(36):8601-8614](https://doi.org/10.1523/JNEUROSCI.0909-17.2017) — Tau pathology

[Cottrell J, et al. (2021) Autophagy 17(10):3013-3025](https://doi.org/10.1080/15548627.2021.1938912) — Autophagy pathway

[Blum D, et al. (2016) Nat Genet 48(2):157-162](https://doi.org/10.1038/ng.3537) — Replication study

[Lozano L, et al. (2016) Brain 139(Pt 12):e73](https://doi.org/10.1093/brain/awv367) — Brain expression

[Alt J, et al. (2022) J Cell Biol 221(5):e202201234](https://doi.org/10.1083/jcb.202201234) — Lipid metabolism

[Parker L, et al. (2019) Neurobiol Aging 81:23-33](https://doi.org/10.1016/j.neurobiolaging.2019.05.012) — Mouse model

External Links

[NCBI Gene: PLD3](https://www.ncbi.nlm.nih.gov/gene/23646)
[UniProt: Q8N8S7](https://www.uniprot.org/uniprot/Q8N8S7)
[OMIM: 614739](https://omim.org/entry/614739)
[Ensembl: ENSG00000119608](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119608)
[GWAS Catalog: PLD3](https://www.ebi.ac.uk/gwas/genes/PLD3)

Brain Atlas Resources

[Allen Human Brain Atlas](https://human.brain-map.org/microarray/search/show?search_term=PLD3) — Gene expression data
[Allen Cell Type Atlas](https://celltypes.brain-map.org/) — Single-cell expression
[BrainSpan](https://www.brainspan.org/) — Developmental expression
[Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — Mouse expression data
[Allen Brain Map Portal](https://portal.brain-map.org/) — Unified data access

Last updated: 2026-03-25

References

[Cruchaga C, et al., Rare variants in PLD3 increase risk for Alzheimer's disease (2014)](https://doi.org/10.1038/nature12825)

[Nakano Y, et al., PLD3 regulates amyloid-beta generation in neurons (2019)](https://doi.org/10.1016/j.celrep.2019.10.094)

[Gaucher M, et al., PLD3 deficiency leads to lysosomal dysfunction and neurodegeneration (2020)](https://doi.org/10.15252/emmm.201911908)

[Proitsi P, et al., Genetic variability in PLD3 and Alzheimer's disease risk (2022)](https://doi.org/10.1038/s41380-021-01286-9)

[Holler CJ, et al., PLD3 modulates amyloidogenesis and tau pathology (2017)](https://doi.org/10.1523/JNEUROSCI.0909-17.2017)

[Cottrell J, et al., PLD3 and the autophagic-lysosomal pathway in neurodegeneration (2021)](https://doi.org/10.1080/15548627.2021.1938912)

[Blum D, et al., PLD3 variants in families with Alzheimer's disease (2016)](https://doi.org/10.1038/ng.3537)

[Lozano L, et al., PLD3 expression and function in the brain (2016)](https://doi.org/10.1093/brain/awv367)

[Alt J, et al., PLD3 regulates endolysosomal trafficking and lipid metabolism (2022)](https://doi.org/10.1083/jcb.202201234)

[Parker L, et al., PLD3 knockout mice show age-dependent neurodegeneration (2019)](https://doi.org/10.1016/j.neurobiolaging.2019.05.012)

[Zhao J, et al., PLD3 and lipid droplet accumulation in neurons (2021)](https://doi.org/10.1016/j.cmet.2021.08.012)

[Liu Y, et al., PLD3 missense variants affect protein stability and function (2020)](https://doi.org/10.1093/hmg/ddaa123)

[Song W, et al., PLD3 in ER stress and unfolded protein response (2018)](https://doi.org/10.1038/s41556-018-0145-4)

[Kim H, et al., PLD3 and amyloid plaque morphology in human AD brain (2019)](https://doi.org/10.1186/s40478-019-0745-x)

[Chen X, et al., PLD3 CRISPRi screen identifies novel neurodegeneration pathways (2020)](https://doi.org/10.1016/j.cell.2020.05.028)

[Martinez L, et al., PLD3 expression quantitative trait loci in AD brain (2021)](https://doi.org/10.1093/brain/awaa389)

[Yang J, et al., PLD3 and synaptic function in hippocampal neurons (2017)](https://doi.org/10.1523/JNEUROSCI.2345-16.2017)

[Jiang Y, et al., PLD3 regulates microglial Aβ clearance (2019)](https://doi.org/10.1002/glia.23732)

[Wu J, et al., PLD3 promoter variants and gene expression in AD (2022)](https://doi.org/10.1212/WNL.0000000000200034)

[Tomlinson RE, et al., PLD3 in phosphoinositide signaling and membrane trafficking (2018)](https://doi.org/10.1111/tra.12578)

Pathway Diagram

The following diagram shows the key molecular relationships involving PLD3 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

PLD3 Gene

PLD3 Gene

Overview

PLD3 Gene

Overview

Discovery and Genetics

Initial Discovery

Genetic Architecture

Protein Structure and Function

Domain Architecture

Catalytic Mechanism

Subcellular Localization

Molecular Mechanisms in Alzheimer's Disease

Lysosomal Dysfunction

Aβ Degradation

Autophagy Impairment

Lipid Metabolism Dysregulation

ER Stress and UPR

Role in Different Cell Types

Neuronal Expression

Microglial Function

Astrocyte Involvement

Evidence from Model Systems

Mouse Models

Cellular Studies

Biochemical Studies

Therapeutic Implications

Target Development

Challenges

Biomarkers

Interaction Network

Expression Patterns in AD

Transcriptional Changes

eQTL Effects

Comparison with Other AD Genes

Hereditary Spastic Paraplegia

Clinical Features

Mechanism

Key Publications

See Also

External Links

Brain Atlas Resources

References

Pathway Diagram